First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study

First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study

Background Avelumab (anti-programmed death ligand 1 (PD-L1)) is approved in multiple countries for the treatment of metastatic Merkel cell carcinoma (mMCC), a rare and aggressive skin cancer. We report efficacy and safety data and exploratory biomarker analyses from a cohort of patients with mMCC tr...

Full description

Bibliographic Details
Main Authors: Jessica C Hassel, Celeste Lebbe, Paul Nghiem, Felix Kiecker, Sandra P D'Angelo, Andrew S Brohl, Sara Georges, Parantu Shah, Barbara Ellers-Lenz, Gülseren Güzel, Laurent Mortier, Jean-Jacques Grob, Nicola Fazio, Natalie Prinzi, Glenn J Hanna
Format: Article
Language:English
Published: BMJ Publishing Group 2021-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/7/e002646.full

Internet

https://jitc.bmj.com/content/9/7/e002646.full

Similar Items